Novartis licensed a preclinical amyloid‑targeting shuttle program from SciNeuro, paying $165 million upfront with up to $1.5 billion in downstream milestones. The collaboration aims to use SciNeuro’s blood‑brain‑barrier shuttle to deliver Alzheimer’s-targeting antibodies into the brain. Novartis will co‑develop the program through early stages and assume global development and commercialization options later. The deal underscores Big Pharma’s continued investment in delivery technologies to overcome the blood‑brain barrier — a bottleneck in neurodegenerative drug development — and adds to a wave of recent shuttle and bispecific transactions focused on CNS therapeutics.